Aehr Test Systems' addressable market looks tiny compared with 200 other AI companies, making it unattractive. x.com 

Aehr Test Systems is key to AI manufacturing and can even be a bottleneck, but at almost 20x revenue through 2028 at the current price, it is stratospherically priced. The risk is giant if something goes wrong for the company or for the AI ramp, and even a slowdown could be deadly at such high valuations. Tech moats are not the same as financial moats. x.com 

Aehr Test Systems stands to benefit because testing is a bottleneck to scaling AI chips. Testing demand is about to surge. Investors did not question its price-to-sales ratio at 120, despite the current P/S objection. x.com  x.com 

Aehr Test Systems is unattractive near $100, at 22.5x sales and 112x forward earnings, even though it will very likely go above $100. Other burn-in names such as AEM Holdings look better placed to play catch-up. x.com 

Trio-Tech's business looks misaligned with what the market needs. It sells burn-in boards that customers can design out quite easily, and Aehr Test Systems could build a competing segment fairly quickly. It is also heavily concentrated in one customer, risky for such a small company; Aehr is concentrated too, but its customers keep coming back for more. x.com 

Aehr Test Systems stands to benefit as testing takes a larger share of expanding semiconductor capex. Teradyne CEO Greg Smith says test's share of semiconductor capex rose from 6.4% in 2025 to 8.1% in the first eight months of 2026, with conditions favorable for prolonged ATE growth. Data-center reliability is pushing testing upstream from systems toward packages and wafers, where Aehr dominates wafer-level burn-in. Aehr lacks a dedicated CPU segment. x.com 

Aehr remains a concentrated, expensive way to own wafer-level photonics burn-in: its 10-K says silicon-photonics customers primarily drove that revenue growth, and FY2027 guidance of $130m-$150m could nearly triple FY2026 sales, yet shares value it at about 20x the guide. Teradyne's acquired photonic-chip test business is not material to its much larger sales; Aehr's top five customers provided 70% of FY2026 revenue, so orders matter more than the headline CPO opportunity. x.com 

Aehr Test Systems is a case of narrative running ahead of the numbers. The bull case is reasonable: a young company with a strong position in silicon carbide burn-in, genuine hyperscaler interest in AI chip burn-in and room to expand into memory and logic. But the latest quarter showed revenue down 43% year over year, with no meaningful order conversion from the AI opportunities yet. Until revenue improves and orders come through more clearly, the story stays ahead of the fundamentals. x.com 

Aehr Test Systems' selloff reflects confusion, not fundamentals: traders dumped the stock after finance sites wrongly listed its earnings for October 6, while a strong order announcement got ignored. Its lead hyperscaler test customer, which already uses Sonoma to test one AI processor in high-volume production, ordered more equipment for a second, newer processor expected to ramp in 2027. x.com 

Sono-Tek's sales are mostly one-time customer purchases in a fairly niche market, which makes the business hard to scale. A post the author replies to says its technology is solid and has fended off Chinese competition well, but that its market may be smaller than management thinks. x.com